AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027

AVITA secures national Medicare payment clarity for RECELL, but commercial impact is unproven.

What the company is saying

AVITA Medical, Inc. (NASDAQ:RCEL, ASX:AVH) announces that the Centers for Medicare & Medicaid Services (CMS) has finalized national physician valuations for skin cell suspension autograft (SCSA) procedures using RECELL, effective January 1, 2027. The company frames this as a major regulatory milestone, emphasizing that nationally published Relative Value Units (RVUs) will replace regionally set valuations and that a new, simplified family of four CPT billing codes will streamline procedure reporting. AVITA’s CEO, Cary Vance, claims these changes will bring simpler billing, greater payment predictability, and a stronger foundation for broader adoption of RECELL as a standard of care. The announcement stresses the removal of separate coding for manual versus automated cell preparation and highlights the new codes’ alignment with body area treated, including special provisions for infants and children. The tone is confident and forward-looking, focusing on anticipated benefits for clinicians and the company’s market position, but does not reference any immediate financial or sales impact.

What the data suggests

CMS has adopted the physician work RVUs recommended by the American Medical Association/Specialty Society RVS Update Committee without modification: for trunk, arms, and/or legs, the initial 100 square centimeters or less is assigned 10.97 RVUs, with each additional 100 square centimeters or part thereof at 0.59 RVUs; for specified areas including the face, scalp, neck, hands, feet, fingers, and toes, the initial 100 square centimeters or less is assigned 11.28 RVUs, with each additional 100 square centimeters or part thereof at 0.98 RVUs. For infants and children, reporting is based on 1% of body area and additional 1% increments. These RVUs will be used nationally for Medicare physician payment calculations starting January 1, 2027, replacing regional MAC valuations. The new CPT code family consolidates eight codes into four, bundles all steps of the SCSA procedure, and removes distinctions between manual and automated cell preparation. No revenue, sales, or adoption data are disclosed; the announcement is strictly regulatory and operational. The only hard numbers are the RVUs and the January 1, 2027 effective date. The commercial and financial impact is not quantified.

Analysis

The announcement is positive in tone, highlighting the finalization of national physician valuations and simplified CPT codes for RECELL procedures, which are concrete regulatory milestones. However, the majority of the claimed benefits—such as broader adoption, payment predictability, and RECELL becoming a standard of care—are forward-looking and contingent on future physician uptake and reimbursement outcomes, which will only begin to materialize after January 1, 2027. No financial or operational performance data (revenue, profit, sales, or adoption rates) are disclosed, so the impact on AVITA's business remains speculative. The language around 'simpler billing,' 'greater payment predictability,' and 'foundation for broader adoption' inflates the signal relative to the actual, measurable progress, which is limited to regulatory and coding changes. There is no indication of a large capital outlay or immediate earnings impact. The data supports that a regulatory milestone has been achieved, but the commercial and financial benefits are unquantified and long-dated.

Risk flags

• ●The commercial impact of these regulatory changes is unproven; no data on physician uptake, procedure volumes, or revenue is provided, so it is unclear whether the new codes will drive broader adoption or higher utilization of RECELL.
• ●Execution risk exists in translating regulatory clarity into market share gains, as physicians and hospitals may be slow to change established practices even with simplified billing and national payment rates.
• ●The timeline to value realization is long, with the new codes and payment structure not effective until January 1, 2027, leaving over a year before any potential financial benefits can be assessed or realized.

Bottom line

AVITA Medical has achieved a key regulatory milestone by securing national Medicare physician payment rates and simplified CPT codes for RECELL SCSA procedures, effective January 1, 2027. The announcement provides detailed RVU values—10.97 and 0.59 for trunk/limbs, 11.28 and 0.98 for specified areas—but does not disclose any financial, sales, or adoption data. The company’s narrative is optimistic about future adoption and payment predictability, but these benefits remain speculative until after the new codes take effect. Investors should recognize that the announcement is regulatory, not commercial, and that the pathway to increased revenue or market share is unproven and long-dated. The most important takeaway is that while reimbursement clarity is a necessary step for broader adoption, actual financial impact will not be visible until well after January 2027.

Announcement summary

(NASDAQ:RCEL, ASX:AVH) AVITA Medical, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has finalized national physician valuations for skin cell suspension autograft (SCSA) procedures performed using RECELL® under the Calendar Year 2027 Medicare Physician Fee Schedule. Effective January 1, 2027, nationally published Relative Value Units (RVUs) will replace valuations set by regional Medicare Administrative Contractors (MACs). CMS is implementing a simplified family of four Current Procedural Terminology (CPT) billing codes to replace the current eight-code structure for SCSA procedures. These changes are intended to simplify procedure reporting and provide physicians with a clearer, more consistent basis for understanding Medicare payment when treating patients with burns and other serious skin injuries. Cary Vance, President and Chief Executive Officer of AVITA Medical, stated that these changes bring simpler billing and greater payment predictability to physicians using RECELL and strengthen the foundation for broader adoption of RECELL as a standard of care. The new Category I CPT code family combines reporting for skin harvesting, cell preparation, and application into a single, bundled SCSA procedure structure. Four codes will now replace the existing eight-code family, simplifying reporting of treatment steps. Codes will distinguish the body area treated and report treatment in increments of 100 square centimeters, with percentage-of-body-area reporting for infants and children. The new structure removes separate coding distinctions for manual and automated cell preparation. CMS-published RVUs will provide a common national basis for calculating Medicare physician payment, replacing regionally determined MAC valuations. In the inpatient setting, Medicare pays hospitals for cases involving RECELL through the Medicare Severity Diagnosis-Related Group (MS-DRG) system, with the RECELL System included among the resources used to treat the patient, and physicians receiving separate payment for their professional services. CMS has finalized facility payment assignments and rates for the new SCSA code family in both hospital outpatient and ambulatory surgery center (ASC) settings. The new physician valuations establish the basis for Medicare payment to physicians for professional services associated with SCSA procedures performed using RECELL, separate from facility payments to hospitals and ASCs. Medicare coverage policies continue to apply. CMS adopted the physician work RVUs recommended by the American Medical Association/Specialty Society RVS Update Committee without modification. For trunk, arms, and/or legs, the initial 100 square centimeters or less is assigned an RVU of 10.97, and each additional 100 square centimeters or part thereof is assigned an RVU of 0.59. For specified areas including the face, scalp, neck, hands and feet and/or fingers and toes, the initial 100 square centimeters or less is assigned an RVU of 11.28, and each additional 100 square centimeters or part thereof is assigned an RVU of 0.98. For infants and children, the codes also provide for reporting based on 1% of body area and additional 1% increments as applicable. The new SCSA code family takes effect January 1, 2027. In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO® are CE-marked in Europe, have TGA certification in Australia, and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.

Disagree with this article?